Quality Control and Complication Screening Programme of Chinese Medicinal Drugs at the First German Hospital of Traditional Chinese Medicine – A Retrospective Analysis

Dieter Melchart^{a,b} Stefan Hager^c Jingzhang Dai^{c,d} Wolfgang Weidenhammer^a

^aCompetence Centre for Complementary Medicine and Naturopathy (CoCoNat), Klinikum rechts der Isar, Technische Universität München, Munich, Germany

^bInstitute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland;

^cTCM hospital Bad Kötzing, Bad Kötzing, Germany

^dBeijing University of Chinese Medicine, Beijing, China

Keywords

Traditional Chinese Medicine · Hepatotoxicity · Herb-induced liver injury · Chinese medicinal drugs · Elevated liver enzyme · Quality control · Screening programme

Summary

Background: The use of drugs derived from plants is a cornerstone of Traditional Chinese Medicine (TCM). Yet, too little is known about risk and safety of Chinese medicinal drugs (CMD). Therefore, the TCM hospital Bad Kötzing has developed a quality control and complication screening programme in order to ensure a safe administration of TCM drugs to their patients. **Methods:** All Chinese medicinal drugs delivered to the hospital between September 1, 2012 and December 31, 2013 entered the quality control program and were screened for microbial contamination, aflatoxin, pesticides and heavy metals. A routinely applied complication screening programme monitored liver enzymes in all patients. Case causality assessment by CIOMS scale and identification of admitted herbs were conducted. Additionally, side effects of patients were identified by a routinely performed web-based documentation system. **Results:** In 5 of 23 investigated samples (21.7%) the initial testing showed microbial contamination (2), pesticide (2) and heavy metals (1). The drugs were tested for authenticity and adulterations, respectively. All 994 patients (mean age 52.6 years; 72.6% female) admitted were available for analysis. 448 (45.1%) of all patients reported having perceived at least one side effect of treatment. They experienced mainly gastrointestinal symptoms (13.6%), neurovegetative symptoms (10.8 %), temporary deteriorations of pain (8.8%), diarrhoea (5.9%), nausea (1.6%) and vomiting (0.5%). Further, 6 patients with a more than 2-fold elevation (compared to maximum normal value or elevated admission values) of ALT were found in the systematic laboratory control with a non-conclusive causality assessment for TCM-drugs. **Conclusion:** Approximate incidence rates and analysed drugs associated with liver damage revealed a low rate of liver injury. Patients should be informed of the gastrointestinal symptoms caused by and potential hepatotoxicity of TCM herbs.

© 2016 S. Karger GmbH, Freiburg

Schlüsselwörter

Traditionelle Chinesische Medizin · Hepatotoxizität · Leberschäden · Chinesische Arzneimittel · Erhöhte Leberwerte · Qualitätskontrolle · Unerwünschte Nebenwirkungen

Zusammenfassung

Hintergrund: Die Verwendung von Arzneipflanzen ist ein Eckpfeiler der traditionellen chinesischen Medizin (TCM). Dennoch existiert immer noch zu wenig Wissen über deren Risiken und Sicherheit. Aus diesem Grunde hat die erste deutsche Klinik für TCM Bad Kötzing zum Schutz der Patienten ein Programm zur Qualitätssicherung der chinesischen Arzneidrogen und deren systematischen Erfassung entwickelt und eingeführt. **Methodik:** Alle in der Zeit vom 1.9.2012 bis 31.12.2013 in die Klinik angelieferten TCM-Arzneidrogen wurden in das Qualitätssicherungsprogramm einbezogen und auf mikrobielle Kontamination, Aflatoxine, Pestizide und Schwermetalle untersucht. Durch eine systematische Laborerfassung von Leberenzymen aller aufgenommenen Klinikpatienten wurden mögliche Leberwertveränderungen dokumentiert, alle verordneten Arzneimittel erfasst und bei Auftreten von möglichen Leberschäden eine Kausalitätsbewertung anhand der leberspezifischen CIOMS-Skala durchgeführt. Schließlich wurden subjektiv unerwünschte Therapiewirkungen über ein webbasiertes Gesundheitsdossier dokumentiert. **Ergebnisse:** In 5 von 23 Arzneimittel-Chargen (21,7%) wurde eine mikrobielle Belastung (n = 2), Pestizide (n = 2) und Schwermetalle (n = 1) gefunden. Die Drogen wurden auf Identität und Reinheit untersucht. Alle im Untersuchungszeitraum in die Klinik aufgenommenen Patienten (n = 994) mit einem Durchschnittsalter von 52,6 Jahren und einem Frauenanteil von 72,6% wurden in die Analyse eingeschlossen. 448 Patienten (45,1%) klagten über mindestens ein unerwünschtes Ereignis, wobei 13,6% über gastrointestinale Beschwerden, 10,8% über neurovegetative Störungen, 8,8% über vorübergehende Schmerz-Verschlimmerungen, 5,9% über Durchfälle, 1,6% über Übelkeit und 0,5% über Erbrechen klagten. In den systematischen Laborkontrollen fanden sich 6 Patienten mit mindestens 2-fach erhöhten GPT-Leberenzymwerten ohne überzeugenden Kausalitätshinweis auf bestimmte TCM-Drogen. **Schlussfolgerung:** Gelegentliche Erhöhungen von Leberenzymwerten als Hinweis auf potentielle Leberschäden durch TCM-Arzneimittel können auftreten. Die Patienten sollten auf die Möglichkeit des Auftretens von gastrointestinalen Beschwerden und von Leberschäden hingewiesen werden.

Background

Between 1991 and 2011, German social health insurance companies have agreed to reimburse the inpatient treatment at TCM hospital Bad Kötzing if patient characteristics, treatments, outcomes and side effects were continuously evaluated. The investigations were performed in collaboration with the Centre of Complementary Medicine and Naturopathy (CoCoNat), Technical University of Munich, and Centre of Pharma Research, University of Munich. The most important therapeutic part of TCM is Chinese medicinal drugs (CMD). They are widely used in Asian communities throughout the world for a broad array of conditions [1]. CMD compounds are of herbal and non-herbal nature and commonly prescribed concurrently. The medications are usually administered as decoctions (tang). A few of them are served as syrups (tang jiang) and medicinal wines (Jiu). Although Chinese drug remedies appear to be relatively safe they are not free of risks, and a number of severe adverse events have been reported [2–7]. A few can cause hepatic injury when given in high concentrations, and some even when used in recommended doses. Patients treated with CMD can be at risk when treated with certain, potentially harmful products (e.g. ephedra). Also pharmacological as well as toxicological interactions with Western medical interventions are sources of potential complications [8]. In a former study, several cases of temporary moderate liver enzyme elevations were observed [9, 10]. It is still unclear to what extent this occurs in a clinical setting. For that reason and because of scientific interest and safety issues, the TCM hospital Bad Kötzing has developed a routinely applied complication screening (CSP) and quality control programme (QCP). CSP consists of a patient reporting outcome system for undesired effect and a standardised laboratory programme for detecting increased laboratory values of liver enzymes. All CMD delivered to the hospital are mainstreamed into the quality control programme. This safety proof aims mainly to exclude drugs which might contain e.g. toxic constituents, possess minor general quality or show contaminations.

Aim

To exemplify quality and safety measures for CMD administered at the TCM hospital Bad Kötzing. Results of preclinical quality proof of drugs, reported side effects and investigated liver enzyme elevations should be documented and discussed.

Setting

TCM hospital Bad Kötzing is equipped with 76 beds for inpatients; 8 Chinese physicians trained at the University of Chinese Medicine in Beijing (China) and one pharmacist collaborate with 6 German physicians. Patients can be referred to the hospital directly by their general practitioner. From the regular monitoring of the treatment process in the TCM hospital it is known that almost all patients in the hospital are usually treated with traditional Chinese drugs. This treatment usually goes along with acupuncture, Chinese manual and relaxation therapy. Drugs are given as raw materials in the form of decoctions and in rare cases as alcohol-based

solutions. Number of prescriptions and of all single drugs as well as duration of treatment is documented systematically. Western therapies are continued or prescribed if necessary.

Methods

Preclinical Quality Control of TCM Medicinal Drugs

Before the TCM drugs can be routinely administered to the patients, all of them have to pass a comprehensive drug control program. To exclude possible falsifications and adulterations of herbal drugs, quantifiable HPLC-peaks and coloured TLC photographs were used for safety and botanical authenticity proof. Further investigations, such as chemical reaction, macro- and microscopy of the drugs, were performed. Special constituents were identified by HPLC, UV spectroscopy, titration and gravimetry according to the German pharmacopoeia *Deutsches Arzneibuch* (1996) and the pharmacopoeia of the People's Republic of China (English edition, 1992; 2005; 2010). This procedure was also applied to any herbal drug combination developed by mixing several individual drugs. In such cases, microscopy, TLC and/or HPLC analysis certificates were presented for individual drugs in order to confirm their authenticity. Therefore, 3–5 drugs from various regions of China were investigated for each species to avoid confusion. Most of the plant drugs were screened for microbial contamination (TAMC, TYMC, salmonella, *Escherichia coli*) aflatoxin (B1, B2, G1, G2) pesticides residues and heavy metals (Pb, Cd, Hg, As). The corresponding necessary tests required special laboratories in which they were performed prior to all other quality investigations. For the European Herbal Drug Regulatory Authority, the following limits for heavy metals are mandatory: lead 5 mg/kg, cadmium 0.9 mg/kg, mercury 0.2 mg/kg, arsenic 2.0 mg/kg. These standards are not mandatory for China. For all test certificates, the following basis was set: for microbiology Ph. Eur 2.6.31; for heavy metal contaminants recommendation Ph. Eur 01/2012; for the requirements of pesticides Ph. Eur 6.1, 2.8.13 and for aflatoxin the aflatoxins ban-V. In relation to TCM drugs without testing requirements for DC-HPLC fingerprint analysis of identity, ad hoc tests took place at the Center for Drug Research of the Ludwig-Maximilians University Munich.

Complication Screening Programme

As part of the routine quality assurance programme, all patients were asked to fill out a web-based questionnaire at admission to the hospital, at discharge and 6 months after discharge, anonymously. The entries were supported by an online health portal, named VITERIO (Virtual Tool for Education, Reporting, Information and Outcome).

An ethical review board was not involved because of the strictly routine character of the outcome study as part of a quality assurance programme. All legal obligations for the protection of personal data were met, and patients gave written informed consent when entering VITERIO.

At discharge, patients were asked to provide information on perceived side effects, i.e. to describe these complaints, symptoms and findings within the electronic documentation system. Furthermore, participants were asked what might have caused their complaints: TCM decoctions, acupuncture, tuina or others.

All inpatients discharged between September 1, 2012, to December 31, 2013 who had been treated with traditional Chinese drugs received routine blood sampling at admission (or not later than one day after admission) and in the last 3 days before discharge. We investigated the frequency of clinically relevant elevated liver enzymes in all consecutive patients treated at the hospital. The enzymes assessed routinely were aspartate aminotransferase (AST) and alanine aminotransferase (ALT). An elevated liver enzyme was defined as any elevation beyond the normal range in patients with normal values at admission, or any elevation beyond admission values in patients with elevated values at admission. Clinically relevant elevations were categorised as multiples of the upper normal limit (N) in 'up to 2-fold', and 'more than 2-fold' (beyond maximum normal value or elevated admission values). Liver injury was assumed as increased ALT activities of at least 2 N, with N as the upper limit of normal [3, 11]. The files of patients with more than 2-fold elevation of ALT were further scrutinised. Diagnosis, treatment (Western and all TCM drugs), duration of treatment, indica-

Table 1. Reason for rejection: Investigations on microbial contamination, heavy metal load and pesticides; number of rejected samples: 5; total number of investigated samples: 23

Name of drug	Identity	Quality	Concentration	Purity	Heavy metal load	Pesticides	Microbiology	Mycotoxine
Aurantii immaturus fructus (Zhishi)	Ø	Ø	Ø	Ø	Ø	Ø	TAMC 4×10^8 KBE/g	Ø
2 × Citri reticulatae pericarpium (Chenpi)	Ø	Ø	Ø	Ø	Ø	dicofof: 1.6 mg/kg; dicofof: 3.6 mg/kg	Ø	Ø
Lonicerae flos (Jin Yinhua)	Ø	Ø	Ø	Ø	lead (Pb); 5.1mg/kg	fenpro-pathrin: 0.05 mg/kg	Ø	Ø
Bupleuri radix (Chaihu)	Ø	Ø	Ø	Ø	Ø	Ø	TAMC 5×10^8 KBE/g; escherichia coli $> 3 \times 10^3$ KBE/g	Ø

Standard values: lead ≤ 5.0 mg/kg; dicofof ≤ 0.5 ; fenpropathrin ≤ 0.03 ; TAMC $\leq 5 \times 10^7$ KBE/g; TYMC $\leq 5 \times 10^5$ KBE/g; escherichia coli $\leq 10^3$.
Ø = normal finding.

tions of previous liver damage and follow-up data were extracted using a standard form, adjusted to the liver-specific Council for International Organisation of Medical Sciences (CIOMS) scale. Case data were used for causality assessment by two independent physicians (D.M., S.H.) and categorised according to the items of the CIOMS scale. Final score of CIOMS may range from -9 to +14 points; resulting causality levels are defined as follows: ≤ 0 points = excluded; 1-2 = unlikely; 3-5 = possible; 6-8 = probable; ≥ 9 = highly probable [3, 11].

Results

Quality Control Program

From September 1, 2012 until end of 2013, all 23 samples of drugs delivered to the hospital were documented and tested. In 5 samples (21.7%) the initial testing showed microbial contamination ($n = 2$), pesticides ($n = 2$) and heavy metals ($n = 1$); besides, no falsifications and adulterations could be found. Dicofof (1.6 mg/kg and 3.6 mg/kg respectively vs. upper limit of normal ≤ 0.5 mg/kg) and fenpropathrin (0.05 mg/kg vs upper limit of normal ≤ 0.03 mg/kg) were the most frequent pesticides. Further, contents of lead (Pb) in Lonicerae flos were slightly increased, and microbial enumeration tests (TAMC, total aerobic microbial count; TYMC, total yeast/ mold count) showed elevated levels of colony count. All contaminated drugs were excluded from the routine administration. Table 1 shows the results of all investigations.

Complication Screening Program

We surveyed 994 consecutive patients treated with TCM drugs at the hospital. Seventy-three percent of patients were female, the mean (SD) age was 53.5 (12.8) years, most of them experienced psychosomatic diseases, and the mean (SD) hospital stay was 26.2 (5.2) days. Additional diagnoses were e.g. back pain, hypertension and sleep disturbances (table 2).

448 (45.1%) of all patients reported at least one side effect of the treatment. 16 answers were invalid; 432 (43.5%) patients were included into the analysis (table 3). They experienced mainly gastro-

Table 2. Patient characteristics of the study sample ($n = 994$)

Patient characteristics	
Gender	
Female, %	72.6
Age in years, mean $\pm$ sd	
Less than 41 years old, %	52.6 $\pm$ 12.4
41-60 years old, %	13.5
More than 60 years old, %	58.3
Principal diagnoses (ICD 10)	
F54 psychological factors of different classified diseases, %	29.9
F45 somatoform disorder, %	20.9
F33 recurrent depression, %	14.2
F32 episode of depression, %	11.8
F43 maladaptation %	5.8
Additional diagnoses (ICD 10)	
M54 back pain, %	36.0
I10 hypertension, %	20.4
F45 somatoform disorder, %	17.7
M79 chronic pain disorder in soft tissue, %	16.3
G47 sleep disturbances, %	12.9
Days spent in the hospital, mean $\pm$ sd	26.2 $\pm$ 5.2

intestinal symptoms 135 (13.6%), neurovegetative symptoms 107 (10.8 %), temporary deteriorations of pain 88 (8.8%), diarrhoea 59 (5.9%), nausea 16 (1.6%) and vomiting 5 (0.5%). 186 (18.7%) patients showed a various range of other symptoms. All participants were asked to attribute these side effects to certain interventions like decoctions of TCM drugs, acupuncture, tuina, qigong and others. The majority of 257 (59.4%) from 432 reporting patients and 38.6% of all patients respectively presumed a causative relation between side effects and decoctions (table 3). Diarrhoea, gastrointestinal and neurovegetative symptoms were the most commonly mentioned disorders in this perspective (table 3). Gastrointestinal symptoms appeared primarily as meteorism (flatulence) and abdominal pain. TCM decoctions were administered with 4 up to 5 prescriptions of individual herbs with a mean number of about 11 drugs (minimum

Table 3. Reported side effects of 432 patients between January 9, 2012 and December 31, 2013 (N = 994); multiple responses possible

Patients, n, %	Diarrhoea, 59 (5.9)	Nausea, 16 (1.6)	Vomiting, 5 (0.5)	Other gastrointestinal symptoms, 135 (13.6)	Neurovegetative symptoms, 107 (10.8)	Detoriation of pain, 88 (8.8)	Others, 186 (18.7)	Total, 432 (43.5)
Decoction	46	11	4	103	61	36	104	257
Acupuncture	0	0	0	2		12	7	25
Tuina	0	0	0	0	5	8	9	18
Qigong	1	0	0	1	0	2	3	7
Others	12	5	1	29	33	30	63	125

Table 4. Number of patients (n) with normal values and multiples of the upper normal limit (N) at discharge with respect to alanine aminotransferase (ALT) and aspartate aminotransferase (AST); total patients = 994

Admission	Discharge				
Within normal* range	normal	N >1 <2	N >2	N >6	N >10
ALT, n = 948	891	53	2	1	1
AST, n = 966	959	5	2	0	0
Above normal* range		N >1 <2	N >2	N >3	
ALT, n = 46		44	1	1	
AST, n = 28		25	3	0	

*Norm limits of AST and ALT: 35 U/l (female); 50 U/l (male).

6 to maximum 19 components) during the hospital stay. Dose rate for each component was 6–10 g. Total dose rate per day and prescription was about 95 g served in two decoctions a day.

Further, we investigated the frequency of clinically relevant elevated liver enzymes in all survey participants. Table 4 shows the number of patients at discharge with normal values and multiples of the upper normal limit $N >1 <2$, $N >2$, $N >6$ and $N >10$ of ALT and AST. 935 patients had normal values of liver enzymes at admission to the hospital. In 53 cases, laboratory results showed elevated ALT values in the category of $N >1 <2$ of the upper normal limit. Two patients showed multiples of both $N >2$ and $N >6$ in ALT. In comparison, AST values were elevated only 2-fold in only two patients. One patient showed a more than 10-fold higher expression of ALT (table 4).

Table 4 also shows the number of patients (n) at discharge with multiples of the increased value at admission (N) of ALT and AST. ALT and AST values measured in 46 and 28 patients, respectively, whose values were increased at admission, showed a slight elevation ($N >1 <2$) in 44 and 25 cases, respectively. In the categories $N >2$ and $N >3$ only one patient each with increased ALT values was detected. In contrast, 3 patients each were detected with increased AST values (table 5). In 4 cases elevated ALT values improved slightly, but did not return to normal levels.

Details of the 6 patients with a more than 2-fold elevation (compared to maximum normal value or elevated admission values) of ALT are shown in table 5. Five female patients with different psychosomatic disorders (ICD-9: F31-F54) and one male patient with colitis ulcerosa (ICD-9 K51.9) were affected by hepatotoxicity. Two of these patients showed increased liver enzymes at admission (patients 5 and 6). All 6 patients were treated with decoctions twice a day and 15–26 drugs with dose rates between 30 g and 102 g per day. In addition to TCM drugs, they all received conventional drug

treatment that was initiated prior to admission. Most of the conventional drugs (not in patient 2) have been associated with hepatotoxicity (celecoxib, mesalazin, pantoprazol, tocilizumab, zolpidem). Patient 1 and 3 suffered from gastrointestinal symptoms, such as diarrhoea, meteorism and abdominal pain during the hospital stay. In all patients, other causes of acute liver injury were excluded on a clinical level. Only patient 5 showed a history of hepatitis B. Control check-ups within the first 8 weeks after discharge and cessation of TCM drugs were denied by two patients (patient 4 and 6). In patient 1 and 3 ALT values returned to normal; patient 2 and 5 still had slight enhanced levels, but showed >50% decrease between ALT peak and N. CMD treatment was continued only in patient 5, after liver enzyme values returned to normal. A causal relationship between ALT elevation and TCM drug therapy was assessed with CIOMS scale. Total scores of CIOMS scale ranged from 0 to 3 points with a resulting causality rated as ‘possible’ for patient 2; as ‘unlikely’ for patients 3–6; and as ‘excluded’ for patient 1.

To identify drugs which may be associated with an increased risk of ALT elevations, the frequencies of prescribed drugs in patients with elevated ALT values and in the 6 cases with more than 2-fold elevated values respectively were compared with the prescription pattern of all patients without elevated liver enzymes (table 6). Data of drug prescriptions were available from 876 patients 739 of which had normal ALT levels, 137 elevated values and 6 more than 2-fold elevated values, respectively. Additionally, in 383 patients self-reported side effects and frequency of prescribed drugs were matched with results from the other groups. Table 6 demonstrates the most frequently prescribed herbs: *Achyranthis bidentatae radix* (63.5%), *Paeoniae rubra radix* (51.3%), *Bupleuri radix* (51.1%), *Astragali radix* (49.0%), *Aurantii immaturus fructus* (44.5%), *Scutellariae radix* (43.6%) and *Dipsaci radix* (41.1%). No noticeable differences regarding the frequency of prescribed drugs

Table 5. Six cases with a more than 2-fold elevation of alanine aminotransferase (ALT) values at discharge over maximal normal values/elevated admission value

Case, sex, age (years)	Diagnoses/findings at admission (ICD 10)	Enzyme*	Admission, U/l	Discharge, U/l	Control, U/l	Drugs, days of use, dose rate per day (g), n	Co-medication	Causality assessment CIOMS, score/grading	Clinical remarks
1, female, 52	somatoforme disorder (F45.40); chronic polyarthritis, destructive (M05.90); tension headache, drug-induced (G45.2)	AST; ALT	20.9; 15.4	324; 361	21; 15	21, 22, 17 days à 78 g, 5 days à 30 g	naloxon/tildin as needed; prednisolon 1 × 10 mg; celecoxib 100 mg; tocilizumab intravenous (every 7th week)	total score: 0; causality rating: excluded ^a	symptoms: watery diarrhoea; concomitant drugs as basic therapy known as hepatotoxins; interaction with herbs?; no alcoholism; no non-drug causes
2, female, 62	neurasthenia (F48.0); fibromyalgia (M79.70); tinnitus (H93.1)	AST; ALT	14.9; 13.6	99; 221	14; 41	25, 18, 72 g	L-thyroxin; pancreatin; vitamin D3	total score: 3; causality rating: possible ^a	no gastrointestinal symptoms during inpatient stay; 10 kg weight loss (undesired) within 4 months before admission; no alcoholism, no non-drug causes; food intolerance known
3, female, 68	chronic pain syndrom (F 45.41); sleep disorder (G47.0); obstipation (K 59.0)	AST; ALT	30; 26.9	49.0; 83.3	35; 31	26, 28, 14 days à 78 g, 7 days à 96 g, 7 days à 102 g	zolpidem 5 mg	total score: 2; causality rating: unlikely ^a	symptoms: meteorism; diarrhoea; abdominal pain; concomitant drug known as hepatotoxin; interaction?; no alcoholism; no non-drug causes, food intolerance known
4, female, 57	bipolar disorder (F31.3); depressive mood; anxiety disorder; chronic back pain (M54.90); osteoarthritis (M15.9)	AST; ALT	27.8; 34.6	39.3; 98.7	patient refused	24, 27, 5 days à 80 g, 10 days à 72 g, 12 days à 90 g	pantoprazol 40 mg; amitriptylin 100 mg; citalopram 40 mg	total score: 2; causality rating: unlikely ^a	no gastrointestinal symptoms; low back pain since 20 years with high analgesic use; metabolic disorders (e.g. high levels of blood fat), no alcoholism, no non-drug causes
5, male, 49	colitis ulcerosa (K51.9); behavioural disorder (F54)a	AST; ALT	33.3; 100	56.2; 313	151, 26; 394 63; 14 days later	18, 22, 78 g	cortison 10 mg; omeprazole 20 mg; mesalazin 400 mg	total score: 2; causality rating: unlikely ^a	no gastrointestinal symptoms; hepatitis B in history; no alcoholism
6, female, 43	posttraumatic stress disorder (F43.1); chronic pain syndrome (R52.1; T07); obesity (E66.9)	AST; ALT	20.3; 40.5	46.5; 88.6	patient refused	15, 22, 19 days à 84 g, 3 days à 45g	pregabalin 100 mg; pantoprazol 40 mg; duloxetine 60 mg	total score: 1; causality rating: unlikely ^a	no gastrointestinal symptoms; no non-drug causes; no alcoholism

*Norm limit of AST and ALT: 35 U/l (female); 50 U/l (male)

^aMedication suspected for hepatotoxicity

Table 6. Most frequently prescribed drugs in all 739 patients with normal values vs. 137 patients with elevated values of liver enzymes vs 383 patients with side effects

Name of drug	Patients without elevation, n = 739		Patients with elevated liver enzymes, n = 137		Patients with more than 2-fold elevation, n = 6		Patients with subjective adverse reactions, n = 383	
	n	%	n	%	n	%	n	%
Achyranthis bidentatae radix	476	64,4	80	61.1	5	83.3	242	63.2
Paeoniae rubra radix	382	51,7	67	51.1	5	83.3	201	52.5
Bupleuri radix	385	52,1	63	48.1	1	16.7	204	53.3
Astragali radix	373	50,5	56	42.7	5	83.3	194	50.7
Aurantii immaturus fructus	344	46,5	46	35.1	3	50.0	173	45.2
Scutellariae radix	323	43,7	59	45.0	4	66.7	176	46.0
Dipsaci radix	298	40,3	62	47.3	4	66.7	159	41.5
Ligustici chuanxiong rhizoma	294	39,8	50	38.2	2	33.3	149	38.9
Loranthi ramulus	278	37,6	58	44.3	3	50.0	147	38.4
Aurantii fructus	284	38,4	33	25.2	1	16.7	142	37.1
Sparganii tuber (rhizoma)	278	37,6	38	29.0	2	33.3	140	36.6
Bambusae caulis in taeniam	258	34,9	49	37.4	2	33.3	146	38.1
Poria (Stücke)	241	32,6	43	32.8	1	16.7	118	30.8
Curcumae longae rhizoma	239	32,3	37	28.2	4	66.7	118	30.8
Ligustri lucidi fructus	226	30,6	39	29.8	1	16.7	116	30.3
Coicis semen	208	28,1	44	33.6	1	16.7	117	30.5
Atractylodis rhizoma	215	29,1	36	27.5	3	50.0	111	29.0
Citri reticulatae pericarpium	214	29,0	32	24.4	1	16.7	127	33.2
Magnoliae officinalis cortex	185	25,0	34	26.0	1	16.7	111	29.0
Cinnamomi ramulus	170	23,0	46	35.1	1	16.7	91	23.8
Notopterygii rhizoma seu radix	172	23,3	40	30.5	0		100	26.1
Angelicae pubescentis radix	168	22,7	41	31.3	0		99	25.8
Liquidambaris fructus	173	23,4	27	20.6	2	33.3	81	21.1
Mori ramulus	152	20,6	38	29.0	1	16.7	85	22.2
Curcumae radix	151	20,4	18	13.7	2	33.3	76	19.8
Cuscutae semen	143	19,4	22	16.8	0		66	17.2
Paeoniae alba radix	143	19,4	17	13.0	0		67	17.5
Pinelliae praeparatae rhizoma	134	18,1	18	13.7	2	33.3	66	17.2
Lycii fructus	120	16,2	17	13.0	1	16.7	50	13.1
Tribuli fructus	122	16,5	13	9.9	0		62	16.2
Angelicae dahuricae radix	120	16,2	12	9.2	0		66	17.2
Angelicae sinensis radix	108	14,6	17	13.0	0		52	13.6
Corydalis rhizoma	111	15,0	13	9.9	0		56	14.6
Spatholobi caulis	107	14,5	12	9.2	0		68	17.8
Persicae semen	100	13,5	17	13.0	0		57	14.9
Lumbricus (t)	107	14,5	9	6.9	1	16.7	47	12.3
Polygalae radix	103	13,9	12	9.3	0		45	11.7
Albiziae cortex	101	13,7	12	9.3	0		46	12.0
Lycopodii herba	99	13,4	14	10.7	0		50	13.1
Carthami flos	106	14,3	6	4.7	0		51	13.1
Codonopsis pilosulae radix	92	12,4	20	15.3	2	33.3	58	15.1
Epimedii herba	94	12,7	14	10.7	1	16.7	55	14.4
Meliae toosendan fructus	85	11,5	17	13.0	1	16.7	51	13.3
Ledebouriiellae radix	88	11,9	10	7.6	1	16.7	44	11.5
Phellodendri cortex	83	11,2	6	4.6	0		39	10.2
Lycopi herba	79	10,7	6	4.6	0		31	8.1
Prunella spica	30	4,1	11	8.5	0		16	4.2
Pyrrosiae folium	6	8	4	3.1	0		2	0.5

between the groups were found. For Bupleuri radix a risk ratio (RR) of 0.19 (95% confidence interval (CI): 0.01–1.66) for a more than 2-fold ALT elevation could be derived. The RR rates for Astragali radix and Scutellariae radix were 5.21 (95% CI: 0.60–119.75) and 2.59 (95% CI: 0.41–20.24) respectively.

Finally, hepatotoxicity of the most important published TCM drugs was compared (table 7). In 4 and 3 of 6 patients with liver

injury, (N >2 in ALT as the upper limit of normal) herbs with potential hepatotoxicity, i.e. Scutellariae radix (Huanquin) and Rhei radix et rhizome (Dahuang), and Cassiae semen (Juemingzi) and Meliae toosendan fructus (Chuanlianzi) respectively were applied. Prescriptions containing Scutellariae radix and Rhei radix et rhizome were administered to patient 2 and 6; patient 3 received all 4 suspicious drugs during hospital stay for more than 4 weeks.

Table 7. TCM drugs showing potential hepatotoxicity; frequency of their use in TCM hospital; frequency in patients with elevated liver enzymes and patient-reported adverse reactions, respectively

Reported hepatotoxicity of TCM drugs / name of drug	Total patient sample, n = 876		Patients with elevated liver enzymes, n = 137		Patients with more than 2-fold elevation, n = 6		Patients with subjective adverse reactions, n = 383	
	n	%	n	%	n	%	n	%
Agkistrodon (t)/Qishe	0		0		0		0	
Alismatis rhizoma/Zexie	30	3.4	4	3.1	0		10	2.6
Artemisia capillaris/yinchen hao	0		0		0		0	
Bombyx batryticatus (t)/Baijiangcan	58	6.6	4	3.1	0		25	6.5
Bupleurum/chaihu	448	51.1	63	48.2	0		201	53.3
Cassiae semen/Juemingzi (senna)	40	4.6	3	2.3	1	16.7	16	4.2
Dictamni radicis cortex/Baixianpi	22	2.5	2	1.6	0		12	3.1
Ephedrae herba/Mahuang	17	1.9	2	1.6	0		6	1.6
Galla chinensis/Wubeizi	3	0.3	0		0		1	0.3
Ginseng radix/Renshen	1	0.1	1	0.8	0		0	
Glycyrrhizae radix/gancao	16	1.8	0		0		7	1.8
Meliae toosendan fructus/Chuanlianzi	102	11.6	17	13.2	1	16.7	51	13.3
Menthae herba/Bohe	58	6.6	7	5.3	0		22	5.7
Oldenlandiae diffusa herba/Baihuasheca	1	0.1	1	0.8	0		0	
Polygoni cuspidati rhizoma/Huzhang	0		0		0		0	
Polygoni multiflora caulis/Shouwuteng	31	3.5	1	0.8	0		13	3.5
Polygoni multiflori radix/Heshouwu	4	0.5	0		0		0	
Puerariae radix/Gegen	35	4.0	8	6.2	0		12	3.1
Punicae granati pericarpium/Shiliupi	0		0		0		0	
Psoraleae fructus/buguzhi	33	3.8	8	6.2	0		15	3.9
Rhei radix et rhizoma/Dahuang	74	8.4	12	9.3	3	50.0	41	10.7
Rheum palmatum/Dahuang	0		0		0		0	
Scolopendra (t)/Wugong	0		0		0		0	
Scorpio Buthus martensii/Quanxie	3	0.3	0		0		1	0.3
Scutellariae radix/Huangqin	382	43.6	59	45.0	4	66.7	146	46.0
Trichosanthis radix/Tianhuafen	1	0.1	11	8.5	0		0	
Tripterygii wilfordii radix/Leigongteng	0		0		0		0	
Xanthii fructus/Cangerzi	19	2.0	3	2.3	0		5	1.3

Discussion

Plants are natural producers of chemical substances, enabling treatment of human ailments since ancient times. Many of them are harmless or have only minor and transient adverse effects. Some herbal chemicals in medicinal plants of traditional and modern medicine, however, carry the risk of herb-induced liver injury (HILI) when given in high concentrations, and some even when used in recommended doses [12, 13]. In many cases, the specific TCM drug that is responsible for the liver injury is unclear. In order to ensure the quality of the TCM drugs given to the patients at the TCM hospital Bad Kötzing, a comprehensive pretreatment drug control program as well as a complication screening program has been installed. Gastrointestinal symptoms, hepatotoxicity and interactions causing elevated or decreased drug levels of mainstream medical drugs are some of the safety information that should be given by administering TCM drugs to admitted patients. Since herbal medicines contain more than one pharmacologically active ingredient and are commonly used in combination with other prescribed herbal and conventional drugs, there is a risk of potential herb-drug interactions which might lead to serious clinical consequences [14]. Concurrent administration of herbal and conventional medicines was found in the majority of patients and was maintained in the course of their hospital stay, if necessary. Despite safety concerns, Chinese medicine appears to be relatively

safe with comparatively few reports of adverse reactions compared with overall drug reports. A recent prospective population-based study from Iceland [15] found an annual incidence rate of drug-induced liver injury (DILI) of approximately 19 cases per 100,000 habitants per year. The most commonly implicated drugs in this general population were amoxicillin-clavulanate (22%), diclofenac (6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (4%). The median duration of therapy was 20 days (range, 8–77 days). The use of some herbal TCM products carries the rare risk of liver injury [11, 16]. At present, the English literature refers to about 40 single TCM herbs with potential hepatotoxicity [3, 11]. A recent review of Teschke et.al [3] gives a good overview of potentially harmful TCM drugs also used for comparison in our survey. Nevertheless, a list of these drugs still has to be rated carefully. Especially drugs with a high prescription rate, such as Scutellariae radix (Huanquin) and Bupleuri radix (Chaihu), have a RR with an extremely broad CI (Scutellariae radix: 2.59 (95% CI: 0.41–20.24); Bupleuri radix: 0.19 (95%CI: 0.01–1.66).

Based on our data of 994 inpatients admitted to the hospital between September 1, 2012 and December 31, 2013, we assessed the patient-perceived occurrence of reported side effects. The adverse reaction reporting system revealed that 17.6% of all inpatients of the hospital reported gastrointestinal symptoms. 5.7 % of these patients are afflicted by diarrhea, mostly induced by applied decoctions. The reporting system lacks precoded complication lists and thus must be

completed by half-structured interviews. Liver injury was assessed based on ALT levels that were more than 2-fold above the upper limit of normal. 6 from 994 patients within the observational timespan fulfilled this definition. Patients were advised to cease all supplement use and were monitored for signs of significant liver dysfunction. Drug discontinuation and therapy reconciliation are the main measures in patient management to minimize occurrence of acute liver failure. To identify the nature and components of the liver injury, characterisation of the clinical phenotype or pattern of hepatic injury is helpful [10]. Differentiation between hepatocellular, cholestatic or mixed type hepatotoxicity is facilitated by comparing initial ALT and ALP values (ALP serum activities) [3, 11]. Unfortunately, the management of the complication screening program did not yet provide serum level of ALP routinely – a must for the future.

Although side effects decreased in all patients and liver enzyme levels normalised after discontinuing TCM drugs, the hospital is committed to inform patients according to the Summary of Product Characteristics (SPC) guideline. Liver injury occurs in $\geq 1/1,000$ to $\leq 1/100$ cases (uncommon adverse reaction); symptoms of diarrhea occur in $\geq 1/100$ to $< 1/10$ cases (common adverse event).

Risks should be identified and communicated to the academic and medical public. As in conventional pharmaceuticals, the confidence with which a TCM diagnosis of liver injury is made depends to a great extent on the number of previously reported and published cases [17]. Nevertheless, scientific strategy has to keep an eye on a fair benefit-risk ratio in order to balance both impact factors of medical care. Therefore, more financial support from political and research funding authorities is needed to realise a better framework for clinical research.

We assessed the occurrence rate and causality levels according to the criteria of CIOMS (Council for International Organizations of Medical Sciences) scale which is a suitable instrument for causality assessment within clinical routine. Surprisingly, all patients involved in the study showed only a few points on the CIOMS

scale. A systematic data collection assessing continued drug therapy after normalisation of the liver enzymes is still pending and a further challenge for the complication screening programme.

The results comparing the frequency and quality of drug prescriptions in the different groups of the survey have to be interpreted with great caution. There is no simple correlation between the number of cases in which a single drug has been prescribed and an increased risk of adverse events or liver toxicity. An exception could be shown in the analysis of different frequencies of drug prescriptions in the groups ‘all patients’ and ‘patients with liver injury’.

The aim of the quality control program of TCM drugs is to avoid adulteration and contamination of herbal medicinal products. A few years back, the results of the examinations revealed more problems associated with drug contents than with contamination [18]. Nowadays, troubles with contamination are more prominent. The spectrum of contaminations contains dust, fungi, insects, microbes, rodents, parasites, pesticides, toxic heavy metals and/or mainstream drugs [18]. Present examinations of our survey show that heavy metals and pesticides are the most striking contaminants. All mistaken and contaminated drugs were rejected from the routine administration.

Conclusion

Further research on safety of and compliance with traditional Chinese drug treatment is clearly warranted in order to find and teach strategies by which these problems can be anticipated, prevented, or managed.

Disclosure Statement

The authors declare that there is no conflict of interests concerning this paper.

References

- Eardley S, Bishop FL, Prescott P, et al.: A systematic literature review of complementary and alternative medicine prevalence in EU. *Forsch Komplementmed* 2012; 19(suppl 2):18–28.
- Rossi S, Navarro VJ: Herbs and liver injury: a clinical perspective. *Clin Gastroenterol Hepatol* 2014;12:1069–1076.
- Teschke R, Zhang L, Long H, Schwarzenboeck A, Schmidt-Taenzer W, Genthner A, Wolff A, Frenzel C, Schulze J, Eickhoff A: Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases. *Ann Hepatol* 2015;14:7–19.
- Woo HJ, Kim HY, Choi ES, Cho YH, Kim Y, Lee JH, Jang E: Drug-induced liver injury: A 2-year retrospective study of 1,169 hospitalized patients in a single medical center. *Phytomedicine* 2015;22:1201–1205.
- Dağ MS, Aydın M, Öztürk ZA, Türkbeyle IH, Koruk I, Savaş MC, Koruk M, Kadayıfçı A: Drug- and herb-induced liver injury: a case series from a single center. *Türk J Gastroenterol* 2014;25:41–45.
- Zhao P, Wang C, Liu W, Wang F: Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China. *Crit Care Med* 2014;42:e296–299.
- Björnsson ES: Drug-induced liver injury: an overview over the most critical compounds. *Arch Toxicol* 2015; 89:327–334.
- Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs* 2009;69:1777–1798.
- Melchart D, Linde K, Hager S, Kaesmar J, Shaw D, Bauer R, Weidenhammer W: Monitoring of liver enzymes in patients treated with traditional Chinese drugs. *Complement Ther Med* 1999;7:208–216.
- Melchart D, Weidenhammer W, Hager S, Shaw D, Bauer R: Liver enzyme elevations in patients treated with traditional Chinese medicine. *JAMA* 1999;282:28–29.
- Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A: Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. *World J Hepatol* 2014;27:17–32.
- Abdualmjid RJ, Sergi C: Hepatotoxic botanicals – an evidence-based systematic review. *J Pharm Pharmacol* 2013;16:376–404.
- Buchornatavakul C, Reddy KR: Review article: herbal and dietary supplement hepatotoxicity. *Aliment Pharmacol Ther* 2013;37:3–17.
- Fasinu PS, Bouic PJ, Rosenkranz B: An overview of the evidence and mechanisms of herb-drug interactions. *Front Pharmacol* 2012;30:69.
- Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S: Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013;144: 1419–1425.
- LiverTox. Clinical and research information on drug-induced liver injury. herbs and dietary supplements. www.livertox.nih.gov/Herbals_and_Dietary_Supplements.htm (accessed February 26, 2016).
- Melchart D, Hager S, Weidenhammer W, Liao JZ, Söllner C, Linde K: Tolerance of and compliance with traditional drug therapy among patients in a hospital for Chinese medicine in Germany. *Int J Risk Safety Med* 1998;11:61–64.
- Posadzki P, Watson L, Ernst E: Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. *Eur J Clin Pharmacol* 2013;69:295–307.